AbCellera Reports Q2 2025 Business Results & Initiation of a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms ...

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

The summer heat may be the focus for many in Holland this August, but anticipation is growing for the more than $11 million ...

More than one million gallons of hazardous pollutants have been removed from the USS Yorktown as a years-long environmental ...

Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) ProgramRESTORE ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, ...

Net debt and capitalization -- $6.9 million in cash as of June 30, 2025, $6.6 million in debt facilities available as of June ...

Norris must not only sustain his form but also navigate the increasingly tense dynamics within the McLaren garage.

Q2 2025 Management View CEO Rodney Tyler Page highlighted that Cipher "delivered on all previously outlined plans at Black ...

Neymar's positive moment seems to be accompanying him in Santos' training sessions as well.The player posted a video on ...

Transnet and Hotazel Manganese Mines (HMM), a joint venture operated by a wholly owned subsidiary of South32, on Thursday ...